Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal

Infection, Genetics and Evolution

Volumn 7, Issue 3, 2007, Pages 391-398

  Palma, A C ^a   Araujo F ^b   Duque, V ^c   Borges, F ^a   Paixao M T ^d   Camacho, R ^a  

^a HOSPITAL EGAS MONIZ   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

HIV 1; Resistance; Transmission

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AFRICA; AGED; ARTICLE; ASIA; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; PHYLOGENY; PORTUGAL; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ALIGNMENT; SOUTH AMERICA; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, VIRAL; EPIDEMIOLOGY, MOLECULAR; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PORTUGAL; PREVALENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247570910     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2007.01.009     Document Type: Article

References (26)

1. Babic D.Z., Zelnikar M., Seme K., Vandamme A.M., Snoeck J., Tomazic J., Vidmar L., Karner P., and Poljak M. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res. (2006)
2. Carvalho, A.P., Gomes, P., Diogo, I., Gonc ̧alves, M.F., Cabanas, J., Abecasis, A., Lobo, M.C., Camacho, R., 2002a. Molecular epidemiology of HIV-1 Infection in Southern Portugal: results of a 92 weeks survey. Ninth European AIDS Conference (EACS), Warsaw, Poland.
3. Carvalho, A.P., Gomes, P., Diogo, I., Gonc ̧alves, M.F., Camacho, R., 2002b. Molecular epidemiology of HIV-1 Infection in Portugal: evolution for a unique pattern in Europe? Eight European Workshop on Virus Evolution and Molecular Epidemiology, Leuven, Belgium.
4. CDC. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 269 (1993) 729-730
5. Centro de Vigilância Epidemiológica das Doenças Transmissiveis, INSA, 2005. Infecção VIH/SIDA: A Situação em Portugal.
6. de Oliveira T., Deforche K., Cassol S., Salminen M., Paraskevis D., Seebregts C., Snoeck J., van Rensburg E.J., Wensing A.M., van de Vijver D.A., Boucher C.A., Camacho R., and Vandamme A.M. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21 (2005) 3797-3800
7. Duque V., Holguin A., Silvestre M., Gonzalez-Lahoz J., and Soriano V. Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra. Portugal Clin. Microbiol. Infect. 9 (2003) 422-425
8. Escoto-Delgadillo M., Vazquez-Valls E., Ramirez-Rodriguez M., Corona-Nakamura A., Amaya-Tapia G., Quintero-Perez N., Panduro-Cerda A., and Torres-Mendoza B.M. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV. Med. 6 (2005) 403-409
9. Esteves A., Parreira R., Piedade J., Venenno T., Franco M., Germano D.S., Patricio L., Brum P., Costa A., and Canas-Ferreira W.F. Spreading of HIV-1 subtype G and envB/gagG recombinant strains among injecting drug users in Lisbon. Portugal AIDS Res. Hum. Retroviruses 19 (2003) 511-517
10. Esteves A., Parreira R., Venenno T., Franco M., Piedade J., Germano D.S., and Canas-Ferreira WF. Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes. AIDS Res. Hum. Retroviruses 18 (2002) 313-325
11. Gandhi R.T., Wurcel A., Rosenberg E.S., Johnston M.N., Hellmann N., Bates M., Hirsch M.S., and Walker B.D. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin. Infect. Dis. 37 (2003) 1693-1698
12. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids Symp. Ser. (1999) 95-98
13. Hemelaar J., Gouws E., Ghys P.D., and Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 (2006) W13-W23
14. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., D'Aquila R.T., Demeter L.M., Kuritzkes D.R., Pillay D., Schapiro J.M., Telenti A., and Richman D.D. Drug resistance mutations in HIV-1. Top. HIV Med. 11 (2003) 215-221
15. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., Schapiro J.M., Telenti A., and Richman D.D. Update of the drug resistance mutations in HIV-1: fall 2005. Top. HIV. Med. 13 (2005) 125-131
16. Lole K.S., Bollinger R.C., Paranjape R.S., Gadkari D., Kulkarni S.S., Novak N.G., Ingersoll R., Sheppard H.W., and Ray S.C. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J. Virol. 73 (1999) 152-160
17. Masquelier B., Costagliola D., Schmuck A., Cottalorda J., Schneider V., Izopet J., Calvez V., Descamps D., Poggi C., and Brun-Vezinet F. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study. J. Med. Virol. 76 (2005) 441-446
18. Paraskevis D., Magiorkinis E., Katsoulidou A., Hatzitheodorou E., Antoniadou A., Papadopoulos A., Poulakou G., Paparizos V., Botsi C., Stavrianeas N., Lelekis M., Chini M., Gargalianos P., Magafas N., Lazanas M., Chryssos G., Petrikkos G., Panos G., Kordossis T., Theodoridou M., Sypsa V., and Hatzakis A. Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res. 112 (2005) 115-122
19. Ristig M.B., Arens M.Q., Kennedy M., Powderly W., and Tebas P. Increasing prevalence of resistance mutations in antiretroviral-naive individuals with established HIV-1 infection from 1996-2001 in St. Louis. HIV Clin. Trials 3 (2002) 155-160
20. Soriano V., Gomes P., Heneine W., Holguin A., Doruana M., Antunes R., Mansinho K., Switzer W.M., Araujo C., Shanmugam V., Lourenco H., Gonzalez-Lahoz J., and Antunes F. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J. Med. Virol. 61 (2000) 111-116
21. Vandamme A.M., Sonnerborg A., Ait-Khaled M., Albert J., Asjo B., Bacheler L., Banhegyi D., Boucher C., Brun-Vezinet F., Camacho R., Clevenbergh P., Clumeck N., Dedes N., De Luca A., Doerr H.W., Faudon J.L., Gatti G., Gerstoft J., Hall W.W., Hatzakis A., Hellmann N., Horban A., Lundgren J.D., Kempf D., Miller M., Miller V., Myers T.W., Nielsen C., Opravil M., Palmisano L., Perno C.F., Phillips A., Pillay D., Pumarola T., Ruiz L., Salminen M., Schapiro J., Schmidt B., Schmit J.C., Schuurman R., Shulse E., Soriano V., Staszewski S., Vella S., Youle M., Ziermann R., and Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviruse Ther. 9 (2004) 829-848
22. Violin M., Cozzi-Lepri A., Velleca R., Vincenti A., D'Elia S., Chiodo F., Ghinelli F., Bertoli A., d'Arminio M.A., Perno C.F., Moroni M., and Balotta C. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18 (2004) 227-235
23. Wegner S.A., Brodine S.K., Mascola J.R., Tasker S.A., Shaffer R.A., Starkey M.J., Barile A., Martin G.J., Aronson N., Emmons W.W., Stephan K., Bloor S., Vingerhoets J., Hertogs K., and Larder B. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 14 (2000) 1009-1015
24. Weinstock H., Respess R., Heneine W., Petropoulos C.J., Hellmann N.S., Luo C.C., Pau C.P., Woods T., Gwinn M., and Kaplan J. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J. Infect. Dis. 182 (2000) 330-333
25. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., De Luca A., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hemmer R., Hoepelman A., Horban A., Korn K., Kucherer C., Leitner T., Loveday C., MacRae E., Maljkovic I., de Mendoza C., Meyer L., Nielsen C., Op de Coul E.L., Ormaasen V., Paraskevis D., Perrin L., Puchhammer-Stockl E., Ruiz L., Salminen M., Schmit J.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., Vandamme A.M., Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., and Boucher C.A. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192 (2005) 958-966
26. Yerly S., Rakik A., De Loes S.K., Hirschel B., Descamps D., Brun-Vezinet F., and Perrin L. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol. 72 (1998) 3520-3523